Clusterin (Apo J) protects against in vitro amyloid-β(1-40) neurotoxicity

Journal of Neurochemistry

Volumn 67, Issue 3, 1996, Pages 1324-1327

  Boggs, Leonard N ^a   Fuson, Kimberly S ^a   Baez, Melvyn ^a   Churgay, Lisa ^a   McClure, Don ^a   Becker, Gerald ^a   May, Patrick C ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Neurodegeneration; Neuroprotection; Neurotoxicity; Rat hippocampal culture; SP 40,40; Sulfated glycoprotein 2

Indexed keywords

AMYLOID BETA PROTEIN; CLUSTERIN; COMPLEMENTARY DNA; EXCITOTOXIN; HYDROGEN PEROXIDE; KAINIC ACID; LACTATE DEHYDROGENASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; FETUS; FIBROBLAST; HAMSTER; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENILE PLAQUE;

ANIMALIA; CRICETINAE; MAMMALIA;

EID: 0029796172     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.67031324.x     Document Type: Article

References (30)

1. Aksenov M. Y., Aksenov M. V., Butterfield D. A., Hensley K., Vigo-Pelfrey C., and Carney J. M. (1996) Glutamine synthetase-induced enhancement of β-amyloid peptide Aβ(1-40) neurotoxicily accompanied by fibril formation and Aβ fragmentation. J. Neurochem. 66, 2050-2056.
2. Berg D. T., McClure D. B., and Grinnell B. W. (1993) High-level expression of secreted proteins from cells adapted to serum-free suspension culture. Biotechniques 14, 972-978.
3. Bertrand P., Poirier J., Oda T., Finch C. E., and Pasinetti G. M. (1995) Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer's disease. Mol. Brain Res. 33, 174-178.
4. Chiesa R., Angeretti N., Lucca E., Salmona M., Tagliavini F., Bugiani O., and Forloni G. (1996) Clusterin (SGP-2) induction in rat astroglial cells exposed to prion protein fragment 106-126. Eur. J. Neurosci. 8, 589-597.
5. Choi-Miura N.-H., Ihara Y., Fukuchi K., Takeda M., Nakano Y., Tobe T., and Tomita M. (1992) SP-40, 40 is a constituent of Alzheimer's amyloid. Acta Neuropathol. (Berl.) 83, 260-264.
6. Duguid J. R., Bohmont C. W., Liu N., and Tourtellotte W. W. (1989) Changes in brain gene expression shared by scrapie and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 86, 7260-7264.
7. Evans K. C., Berger E. P., Cho C. G., Weisgraber K. H., and Lansbury P. T. Jr. (1995) Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Nail. Acad. Sci. USA 92, 763-767.
8. Finch C. E. and May P. C. (1996) Clusterin expression in the adult brain and responses to neurodegeneration, in Clusterin: Function in Vertebrate Organ Development, Function and Adaption. (Harmony J., ed), in press. R. G. Landis Co., Austin, Texas.
9. Ghiso J., Matsubara E., Koudinov A., Choi-Miura N. H., Tomita M., Wisniewski T., and Frangione B. (1993) The cerebrospinal fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (Apo J), an inhibitor of the complement membrane attack complex. Biochem. J. 293, 27-30.
10. Golabek A. M., Marques M., Lalowski M., and Wisniewski T. (1995) Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci. Lett. 191, 79-82.
11. Jenne D. E. and Tschopp J. (1992) Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem. Sci. 17, 154-159.
12. Lorenzo A. and Yankner B. A. (1994) β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 91, 12243-12247.
13. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β protein into filaments. Nature 372, 92-94.
14. Matsubara E., Frangione B., and Ghiso J. (1995) Characterization of apolipoprotein J Alzheimer's Aβ interaction. J. Biol. Chem. 270, 7563-7567.
15. Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R. E. (1992) β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 379-389.
16. May P. C. and Finch C. E. (1992) Sulfated glycoprotein 2: new relationships of this multifunctional protein to neurodegeneration. Trends Neurosci. 15, 391-396.
17. May P. C., Johnson S. A., Poirier J., Lampert-Etchells M. A., and Finch C. E. (1989) Altered gene expression in Alzheimer's disease brain tissue. Can. J. Neurol. Sci. 16, 473-476.
18. May P. C., Lampert-Etchells M., Johnson S. A., Poirier J., Masters J. N., and Finch C. E. (1990) Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 5, 831-839.
19. May P. C., Gitter B. D., Waters D. C., Simmons L. K., Becker G. W., Small J. S., and Robison P. M. (1992) β-Amyloid in vitro toxicity: lot-to-lot variability. Neurobiol. Aging 13, 605-607.
20. May P. C., Boggs L. N., and Fuson K. S. (1993) Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer's disease amyloid-β neurotoxicity. J. Neurochem. 61, 2330-2333.
21. McGeer P. L., Kawamata T., and Walker D. G. (1992) Distribution of clusterin in Alzheimer brain tissue. Brain Res. 579, 337-341.
22. Oda T., Pasinetti G. M., Osterburg H. H., Anderson C., Johnson S. A., and Finch C. E. (1994) Purification and characterization of brain clusterin. Biochem. Biophys. Res. Commun. 204, 1131-1136.
23. Oda T., Wals P., Osterburg H. H., Johnson S. A., Pasinetti G. M., Morgan Rozovsky I., Stine W. B., Snyder S. W., Holzman T. F., Kraft G. A., and Finch C. E. (1995) Clusterin (ApoJ) alters the aggregation of amyloid β-peptide (Aβ1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp. Neurol. 136, 22-31.
24. Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1993) Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687.
25. Polihronis M., Paizis K., Carter G., Sedal L., and Murphy B. (1993) Elevation of human cerebrospinal fluid clusterin concentration is associated with acute neuropathology. J. Neurol. Sci. 115, 230-233.
26. Schenk D. B., Rydel R. E., May P. C., Little S., Panetta J., Lieberburg I., and Sinha S. (1995) Therapeutic approaches related to amyloid-β peptide and Alzheimer's disease. J. Med. Chem. 38, 4141-4154.
27. Selkoc D. J. (1993) Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 16, 403-409.
28. Simmons L. K., May P. C., Tomaselli K. J., Rydel R. E., Fuson K. S., Brigham S. W., Lieberburg I., Becker G. W., Brems D. N., and Li W. Y. (1994) Secondary structure of β-amyloid peptide correlates with Aβ neurotoxicity in vitro. Mol. Pharmacol. 45, 373-379.
29. Whitson J. S., Mims M. P., Strittmatter W. J., Yamaki T., Morrisett J. D., and Appel S. H. (1994) Attenuation of the neurotoxic effect of a beta amyloid peptide by apolipoprotein E. Biochem. Biophys. Res. Commun. 199, 163-170.
30. Yankner B. A., Duffy L. K., and Kirschner D. A. (1990) Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250, 279-282.